2. Search Result
Search Result
Results for "

stenosis

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112499
    Menaquinone-7
    3 Publications Verification

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 TGF-beta/Smad Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-16657
    TAPI-1
    10+ Cited Publications

    		 MMP NF-κB Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .
    TAPI-1
  • HY-A0119
    Nitroprusside disodium dihydrate
    Maximum Cited Publications
    17 Publications Verification

    Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate

    		 Autophagy Cardiovascular Disease Cancer
    Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .
    Nitroprusside disodium dihydrate
  • HY-W324435
    2,4-Dinitrobenzenesulfonic acid sodium salt

    Sodium 2,4-dinitrobenzenesulfonate; DNBS sodium salt; DNBSO sodium salt

    		 NF-κB p38 MAPK COX Inflammation/Immunology
    2,4-Dinitrobenzenesulfonic acid (DNBS; DNBSO) sodium salt (Sodium 2,4-dinitrobenzenesulfonate) is a classic colitis inducer that relies on activation of the NF-κB p65/COX-2/p38 pathway. As a hapten, 2,4-Dinitrobenzenesulfonic acid sodium salt stimulates the production of immune responses in colonic tissues, triggers oxidative stress and inflammatory reactions, and thereby leads to colonic injury. 2,4-Dinitrobenzenesulfonic acid sodium salt successfully induces models of colitis and ulcerative colitis in rats, causing pathological changes such as ulcers, edema, stenosis, shortening and organ adhesion in the distal colon, along with significant increases in the levels of inflammatory indicators and endoplasmic reticulum stress marker proteins. 2,4-Dinitrobenzenesulfonic acid sodium salt is widely used in studies on the mechanisms related to colitis and ulcerative colitis .
    2,4-Dinitrobenzenesulfonic acid sodium salt
  • HY-P99959
    Unasnemab

    MT-3921; rH116A3

    		 TGF-β Receptor Neurological Disease
    Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
    Unasnemab
  • HY-P3525A
    G-Pen-GRGDSPCA TFA

    		Integrin Others
    G-Pen-GRGDSPCA TFA is an αvβ3-inhibiting RGD peptide. G-Pen-GRGDSPCA can limit neointimal hyperplasia and lumen stenosis after vascular injury, as well as regulate the migration and proliferation of smooth muscle cells. G-Pen-GRGDSPCA TFA can be used in the study of the mechanism of vascular injury repair .
    G-Pen-GRGDSPCA TFA
  • HY-112499S
    Menaquinone-7-d7

    Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-d7
  • HY-112499R
    Menaquinone-7 (Standard)
    3 Publications Verification

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-P3525
    G-Pen-GRGDSPCA

    		Integrin Others
    G-Pen-GRGDSPCA is an αvβ3-inhibiting RGD peptide. G-Pen-GRGDSPCA can limit neointimal hyperplasia and lumen stenosis after vascular injury, as well as regulate the migration and proliferation of smooth muscle cells. G-Pen-GRGDSPCA can be used in the study of the mechanism of vascular injury repair .
    G-Pen-GRGDSPCA
  • HY-116307
    2-Thio-UTP

    		P2Y Receptor Cardiovascular Disease
    2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
    2-Thio-UTP
  • HY-112350
    AGL 2043

    		PDGFR FLT3 Cancer
    AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent .
    AGL 2043
  • HY-112499S1
    Menaquinone-7-13C6

    Vitamin K2-7-13C6; Vitamin K2(35)-13C6; Vitamin MK-7-13C6

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7- 13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-13C6
  • HY-P3082
    SKF 106760

    		Endogenous Metabolite Cardiovascular Disease
    SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
    SKF 106760
  • HY-48813
    Glycoursodeoxycholic acid 3-sulfate

    		Endogenous Metabolite NF-κB Interleukin Related Metabolic Disease
    Glycoursodeoxycholic acid 3-sulfate is a glycine-conjugated sulfated bile acid 3-sulfate, which is produced by SULT2A1-mediated sulfation of glycoursodeoxycholic acid (HY-N1424) in the liver. Glycoursodeoxycholic acid 3-sulfate attenuates the anti-inflammatory effect of glycoursodeoxycholic acid and impairs the inhibitory effect on the IL-17 and NF-κB signaling pathways. Glycoursodeoxycholic acid 3-sulfate shows a significant correlation with aortic flow velocity and BNP in patients with aortic stenosis. Glycoursodeoxycholic acid 3-sulfate is mainly used in related studies such as quantitative analysis, quality control and biochemical experiments; it often serves as a reagent for metabolomics analysis and can also be applied to research related to aortic stenosis .
    Glycoursodeoxycholic acid 3-sulfate
  • HY-182573
    RWJ-58259

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    RWJ-58259 is a selective PAR-1 inhibitor with an IC50 value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .
    RWJ-58259

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: